The Supreme Court could say today whether it will review a case involving a "pay for delay" agreement in which a pharmaceutical company pays generic rivals tens of millions of dollars to hold off from launching copycat versions of medicines. The FTC says the practice costs customers $3.5B a year, while drug firms argue that it protects innovation. Companies that could be affected include Abbott (ABT), Watson (WPI), Merck (MRK), Bristol-Myers Squibb (BMY) and Teva (TEVA).
The Supreme Court could say today whether it will review a case involving a "pay for delay"...
From other sites
Video at CNBC.com (Thu, 12:48PM)
Video at CNBC.com (Thu, 9:40AM)
Video at CNBC.com (Jul 20, 2016)
Video at CNBC.com (Jul 11, 2016)
Video at CNBC.com (Jun 20, 2016)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs